Tools

Leukemias

Leukemia is a cancer that develops in the bone marrow where blood cells are made.

Programs + Services


Blood and Marrow Transplant Program

Explore the Blood and Marrow Transplant Program at Floating Hospital in Boston, and learn more about our treatment for cancer stem cells in children.
More


Leukemias and Lymphomas Program

Contact our Division of Pediatric Hematology/Oncology at Floating Hospital in Boston to learn more about treatment and symptoms of childhood leukemia and lymphoma.
More

Doctors + Care Team

Jason Law, MD

Jason Law, MD

Title(s): Director of Bone Marrow Transplantation; Assistant Professor, Tufts University School of Medicine
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Pediatric hematology, oncology, bone marrow transplant

More Info

Michael Kelly, MD

Michael Kelly, MD

Title(s): Pediatric Hematologist/Oncologist; Principal Investigator, Childrens Oncology Group; Clinical Associate Professor, Tufts University School of Medicine
Department(s): Pediatrics, Pediatric Hematology/Oncology
Appt. Phone: 617-636-5535
Fax #: 617-636-7738

Childhood cancers including leukemia, lymphoma and solid tumors, anemia and bleeding disorders, thrombosis

More Info

Susan K. Parsons, MD, MRP

Susan K. Parsons, MD, MRP

Title(s): Founding Director, Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Diseases; Director, The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies; Professor, Tufts University School of Medicine
Department(s): Pediatrics, Cancer Center, Medicine, Pediatric Hematology/Oncology, Hematology/Oncology
Appt. Phone: 617-636-5168
Fax #: 617-636-6280

Pediatric bone marrow transplantation, long-term quality of life following transplantation, supportive medical and emotional care for patients and families

More Info

Research + Clinical Trials


AALL0932:  Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

This is a protocol for people with newly diagnosed Standard Risk Acute Lymphoblastic Leukemia. The study is broken up into parts. Each part of the study will be exploring different phases of chemotherapy such as Induction, Post-Induction, and Maintenance. In each phase of the study, researchers will be testing different experimental drug regimens versus standard treatments to see which one works better. Additionally, participants will be grouped based on their risk level and may receive different  chemotherapy regimens based on their risk.
More


AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

This study will look at how effective different combinations of chemotherapy are a preventing acute lymphoblastic leukemia from coming back.
More


AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

The aims of this study are to improve treatment for T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy). We want to see if adding bortezomib to the standard treatment reduces the chance that the cancer will come back.
More


Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, can block cancer growth by finding cancer cells and helping to kill them or carrying cancer-killing substances to them. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
More


Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  1. To find out if subjects with down syndrome and standard risk acute myeloid leukemia can be treated with less treatment and still have successful outcomes.
  2. To find out if subjects with down syndrome and high risk acute myeloid leukemia can be successfully treated with stronger chemotherapy.

More


A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

This study looks at how well an antibiotic prophylaxis, called levofloxacin, can prevent bacterial infection from developing in children and young adults receiving intensive cancer treatment or a stem cell transplant. The levofloxacin drug which prevents bacterial infection is experimental.
More

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class pediatric teaching hospital shouldn’t make you and your child feel small.  At Floating Hospital for Children our littlest patients are our biggest priority. This means we’re committed to providing the highest quality of care in a safe, friendly environment.

Learn more
A child in the pediatric emergency department at Floating Hospital for Children.

Floating Ranks With the Best

The Leapfrog Group gave Floating Hospital for Children and Tufts Medical Center an “A” rating for outstanding patient safety in 2014.

Learn more
Floating Hospital for Children has a strong history of innovation.

A Fresh Breath of Air

Floating Hospital for Children began its life as a hospital ship in the Boston Harbor in 1894 before coming onshore permanently in 1931.

Learn more